Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents

NCT02091141 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT02091141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02091141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 14, 2014
Completion date
May 24, 2023
Enrollment
673 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

biliary cancer, bladder cancer, neoplasms, salivary cancer, solid tumors